Hanyang Med Rev.  2018 Jun;38(2):99-102. 10.7599/hmr.2018.38.2.99.

Carbapenem-resistant Enterobacteriaceae in Korea

• Kim J

• KMID: 2431306
• DOI: http://doi.org/10.7599/hmr.2018.38.2.99

Abstract

Carbapenem-resistant Enterobacteriaceae (CRE) has emerged as a major problem of public health. By various resistance mechanisms including carbapenemase, there are few antibiotics to treat CRE infection. Therefore, an infection caused by CRE is associated with a higher mortality rate than those caused by other causative agents. By horizontal transmission of the carbapenemase-producing gene, resistance to carbapenem spreads to other organisms and multi-drug resistance could be induced. The incidence of CRE has increased, and many countries have been troubled with CRE outbreaks. The best way to manage and treat CRE is infection control and prevention against CRE. The aim of this paper is to describe the current status of CRE and clinical implication of CRE infection in Korea. The mechanism which induces resistance to carbapenem as well as carbapenemase-producing gene (a gene that could be transferred to other organisms and then induces resistance to carbapenem) make it difficult to treat CRE infection.

Keyword

Carbapenem-resistant; Carbapenemase; Enterobacteriaceae; Korea; Epidemiology

MeSH Terms

Anti-Bacterial Agents
Disease Outbreaks
Drug Resistance, Multiple
Enterobacteriaceae*
Epidemiology
Incidence
Infection Control
Korea*
Mortality
Public Health
Anti-Bacterial Agents

Reference

1. McKenna M. Antibiotic resistance: the last resort. Nature. 2013; 499:394–396.

2. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P t. 2015; 40:277–283.

3. Goodman KE, Simner PJ, Tamma PD, Milstone AM. Infection control implications of heterogeneous resistance mechanisms in carbapenem-resistant Enterobacteriaceae (CRE). Expert Rev Anti Infect Ther. 2016; 14:95–108.

4. Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis. 2014; 20:1170–1175.

5. KCDC. Disease web statistics system [Internet]. cited 2018 Oct 29. Available from: http://www.cdc.go.kr/npt/biz/npp/ist/bass/bassDissStatsMain.do.

6. CDC. FAQs about choosing and implementing a CRE definition [Internet]. c2015. 2015 Jun 29. 2017 Dec 29. Available from: http://www.cdc.gov/hai/organisms/cre/definition.html.

9. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001; 45:1151–1161.

10. Guh AY, Limbago BM, Kallen AJ. Epidemiology and prevention of carbapenem-resistant Enterobacteriaceae in the United States. Expert Rev Anti Infect Ther. 2014; 12:565–580.

11. Kelly AM, Mathema B, Larson EL. Carbapenem-resistant Enterobacteriaceae in the community: a scoping review. Int J Antimicrob Agents. 2017; 50:127–134.

12. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother. 2009; 53:5046–5054.

13. Nordmann P. Carbapenemase-producing Enterobacteriaceae: overview of a major public health challenge. Med Mal Infect. 2014; 44:51–56.

14. Rhee JY, Park YK, Shin JY, Choi JY, Lee MY, Peck KR, et al. KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea. Antimicrob Agents Chemother. 2010; 54:2278–2279.

15. Kim MN, Yong D, An D, Chung HS, Woo JH, Lee K, et al. Nosocomial clustering of NDM-1-producing Klebsiella pneumoniae sequence type 340 strains in four patients at a South Korean tertiary care hospital. J Clin Microbiol. 2012; 50:1433–1436.

16. Bae IK, Kang HK, Jang IH, Lee W, Kim K, Kim JO, et al. Detection of Carbapenemases in Clinical Enterobacteriaceae Isolates Using the VITEK AST-N202 Card. Infect Chemother. 2015; 47:167–174.

17. Wang Q, Zhang Y, Yao X, Xian H, Liu Y, Li H, et al. Risk factors and clinical outcomes for carbapenem-resistant Enterobacteriaceae nosocomial infections. Eur J Clin Microbiol Infect Dis. 2016; 35:1679–1689.

18. Swaminathan M, Sharma S, Poliansky Blash S, Patel G, Banach DB, Phillips M, et al. Prevalence and risk factors for acquisition of carbapenem-resistant Enterobacteriaceae in the setting of endemicity. Infect Control Hosp Epidemiol. 2013; 34:809–817.

19. Salomao MC, Guimaraes T, Duailibi DF, Perondi MBM, Letaif LSH, Montal AC, et al. Carbapenem-resistant Enterobacteriaceae in patients admitted to the emergency department: prevalence, risk factors, and acquisition rate. J Hosp Infect. 2017; 97:241–246.

20. Tischendorf J, de Avila RA, Safdar N. Risk of infection following colonization with carbapenem-resistant Enterobactericeae: A systematic review. Am J Infect Control. 2016; 44:539–543.

21. Neuner EA, Gallagher JC. Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae. Virulence. 2017; 8:440–452.

22. Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV, et al. Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia. Antimicrob Agents Chemother. 2017; 61:pii: e00883-17.

23. Kohler PP, Volling C, Green K, Uleryk EM, Shah PS, McGeer A. Carbapenem Resistance, Initial Antibiotic Therapy, and Mortality in Klebsiella pneumoniae Bacteremia: A Systematic Review and Meta-Analysis. Infect Control Hosp Epidemiol. 2017; 38:1319–1328.

24. Hauck C, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, et al. Spectrum of excess mortality due to carbapenem-resistant Klebsiella pneumoniae infections. Clin Microbiol Infect. 2016; 22:513–519.

25. Kim YK, Song SA, Lee JN, Oh M, Jo KM, Kim HJ, et al. Clinical factors predicting persistent carriage of Klebsiella pneumoniae carbapenemase-producing carbapenem-resistant Enterobacteriaceae among patients with known carriage. J Hosp Infect. 2017.

26. Kohanski MA, DePristo MA, Collins JJ. Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis. Mol Cell. 2010; 37:311–320.

27. Rhouma M, Beaudry F, Theriault W, Letellier A. Colistin in Pig Production: Chemistry, Mechanism of Antibacterial Action, Microbial Resistance Emergence, and One Health Perspectives. Front Microbiol. 2016; 7:1789.